{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.4","value":"33849.4"},{"groupId":"OG001","spread":"50.5","value":"123698.8"},{"groupId":"OG002","spread":"38.7","value":"208795.6"},{"groupId":"OG003","spread":"32.5","value":"498570.5"},{"comment":"Insufficient data to calculate geometric mean and geometric coefficient of variation","groupId":"OG004","spread":"NA","value":"NA"},{"groupId":"OG005","spread":"6.8","value":"161090.8"},{"groupId":"OG006","spread":"344.0","value":"149520.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"title":"Week 1 AUC(0-24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.7","value":"223886.8"},{"groupId":"OG001","spread":"45.7","value":"818109.9"},{"groupId":"OG002","spread":"27.5","value":"1579811.4"},{"groupId":"OG003","spread":"37.5","value":"3500751.4"},{"comment":"Insufficient data to calculate geometric mean and geometric coefficient of variation","groupId":"OG004","spread":"NA","value":"NA"},{"groupId":"OG005","spread":"24.3","value":"1123811.4"},{"groupId":"OG006","spread":"357.5","value":"1034157.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"title":"Week 1 AUC(0-336)"},{"categories":[{"measurements":[{"comment":"A geometric mean coefficient of variation cannot be calculated for data from only 1 participant.","groupId":"OG000","spread":"NA","value":"66000.0"},{"groupId":"OG001","spread":"21.9","value":"184610.2"},{"groupId":"OG002","spread":"16.7","value":"224875.8"},{"groupId":"OG003","spread":"55.4","value":"466764.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"Week 9 (steady state) AUC(0-24)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"description":"AUC(0-24) = AUC from time 0 to 24 hours (1 day); AUC(0-336) = AUC from time 0 to 336 hours (14 days). Calculated from plasma concentrations measured from samples collected at the time points below.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG000","title":"CTX-471 Monotherapy 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG001","title":"CTX-471 Monotherapy 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG002","title":"CTX-471 Monotherapy 0.6 mg/kg"},{"description":"1.2 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG003","title":"CTX-471 Monotherapy 1.2 mg/kg"},{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG004","title":"CTX-471 Combination 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG005","title":"CTX-471 Combination 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG006","title":"CTX-471 Combination 0.6 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Set: all patients who received CTX-471 (and pembrolizumab in combination arms) and had at least 1 post-treatment measurement and no protocol deviations or events affecting the validity of the results","reportingStatus":"POSTED","timeFrame":"Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.","title":"Area Under the Serum Concentrations of CTX-471 Versus Time Curve (AUC)","type":"SECONDARY","unitOfMeasure":"h∙ng/mL"}